Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the epstein-barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5559-5577

  Arredouani, Mohamed S ^a   Bhasin, Manoj K ^a   Sage, David R ^a   Dunn, Laura K ^a   Gill, Michael B ^a   Agnani, Deep ^a   Libermann, Towia A ^a   Fingeroth, Joyce D ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD48 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; HISTONE; HLA ANTIGEN CLASS 2; INTERLEUKIN 21 RECEPTOR; MELANOMA ANTIGEN; PROTEIN C JUN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; C2TA GENE; CD45 GENE; CD48 GENE; CELL ADHESION; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE; GENE EXPRESSION; GENE TRANSFER; GENETIC ANALYSIS; HLA II GENE; HUMAN; HUMAN CELL; IL21R GENE; INTRACELLULAR SIGNALING; MIC2 GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PTPRCAP GENE; TEMPORAL ANALYSIS; UBIQUITINATION; UPREGULATION; VIRUS ATTACHMENT; VIRUS CELL INTERACTION;

B-LYMPHOCYTES; CELL DIFFERENTIATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTANT PROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, COMPLEMENT 3D; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; VIRUS ATTACHMENT;

EID: 84899121279     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03099-13     Document Type: Article

References (56)

1. Rickinson AB, Kieff E. 2007. Epstein-Barr Virus, p 2655-2700. In Knipe DM, Howley PM (ed), Fields virology, vol 2. Lippincott, Williams & Wilkins, Philadelphia, PA.
2. Luzuriaga K, Sullivan JL. 2010. Infectious mononucleosis. N. Engl. J. Med. 362:1993-2000. http://dx.doi.org/10.1056/NEJMcp1001116.
3. Tanner J, Weis J, Fearon D, Whang Y, Kieff E. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50:203-213. http://dx.doi.org/10 .1016/0092-8674(87)90216-9.
4. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. 1984. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U. S. A. 81:4510-4514. http://dx.doi .org/10.1073/pnas.81.14.4510.
5. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. 1987. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61:1416-1420.
6. Frade R, Barel M, Ehlin-Henriksson B, Klein G. 1985. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. U. S. A. 82:1490-1493. http://dx.doi.org/10.1073 /pnas.82.5.1490.
7. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE, Allday MJ, Patel A, Dave SS, Kim W, Hu K, Guo J, Tainter D, Rusyn E, Luftig MA. 2010. An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 8:510-522. http://dx.doi.org/10.1016/j.chom .2010.11.004.
8. Thorley-Lawson DA. 2001. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:75-82. http://dx.doi.org/10.1038/35095584.
9. Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM. 2006. Characterization of humancomplement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J. Immunol. 177:383-394. http://www.jimmunol.org/content/177/1/383.long.
10. Roozendaal R, Carroll MC. 2007. Complement receptors CD21 and CD35 in humoral immunity. Immunol. Rev. 219:157-166. http://dx.doi .org/10.1111/j.1600-065X.2007.00556.x.
11. Mongini PK, Jackson AE, Tolani S, Fattah RJ, Inman JK. 2003. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis. J. Immunol. 171:5244-5254. http: //www.jimmunol.org/content/171/10/5244.long.
12. Tedder TF, Zhou LJ, Engel P. 1994. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today 15:437-442. http://dx.doi .org/10.1016/0167-5699(94)90274-7.
13. Barel M, Balbo M, Le Romancer M, Frade R. 2003. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human cell surface triggers pp60src and Akt-GSK3 activities upstream and downstream to PI 3-kinase, respectively. Eur. J. Immunol. 33:2557-2566. http://dx.doi .org/10.1002/eji.200324059.
14. Gill MB, Roecklein-Canfield J, Sage DR, Zambela-Soediono M, Longtine N, Uknis M, Fingeroth JD. 2004. EBV attachment stimulates FHOS/ FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21. J. Cell Sci. 117:2709-2720. http://dx.doi.org/10.1242/jcs.01113.
15. Tessier J, Cuvillier A, Glaudet F, Khamlichi AA. 2007. Internalization and molecular interactions of human CD21 receptor. Mol. Immunol. 44: 2415-2425. http://dx.doi.org/10.1016/j.molimm.2006.10.014.
16. Filippini G, Griffin S, Uhr M, Eppenberger H, Bonilla J, Cavalli F, Soldati G. 1998. A novel flow cytometric method for the quantification of p53 gene expression. Cytometry 31:180-186. http://dx.doi.org/10.1002 /(SICI)1097-0320(19980301)31:3 180::AID-CYTO5=3.0.CO;2-P.
17. Lazarus H, Barell EF, Krishan A, Livingston DM, Harris K, Schlossman SF, ChessL. 1978. Characterization of auniquecell line(LAZ221)fromhumanacute lymphocytic ("null" cell) leukemia. Cancer Res. 38:1362-1367.
18. Simmons D, Makgoba MW, Seed B. 1988. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature 331:624-627. http://dx.doi.org/10.1038/331624a0.
19. Fingeroth JD, Benedict MA, Levy DN, Strominger JL. 1989. Identification of murine complement receptor type 2. Proc. Natl. Acad. Sci. U. S. A. 86:242-246. http://dx.doi.org/10.1073/pnas.86.1.242.
20. Prota AE, Sage DR, Stehle T, Fingeroth JD. 2002. The crystal structure of human CD21: implications for Epstein-Barr virus and C3d binding. Proc. Natl. Acad. Sci. U. S. A. 99:10641-10646. http://dx.doi.org/10.1073 /pnas.162360499.
21. Shapiro AL, Vinuela E, Maizel JV, Jr. 1967. Molecular weight estimation of polypeptide chains by electrophoresis in SDS-polyacrylamide gels. Biochem. Biophys. Res. Commun. 28:815-820. http://dx.doi.org/10.1016 /0006-291X(67)90391-9.
22. Kuhn-Hallek I, Sage DR, Stein L, Groelle H, Fingeroth JD. 1995. Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells. Blood 85:1289-1299.
23. Skare J, Strominger JL. 1980. Cloning and mapping of BamHI endonuclease fragments of DNA from the transforming B95-8 strain of Epstein-Barr virus. Proc. Natl. Acad. Sci. U. S. A. 77:3860-3864. http://dx.doi.org /10.1073/pnas.77.7.3860.
24. Benjamin D, Sharma V, Knobloch TJ, Armitage RJ, Dayton MA, Goodwin RG. 1994. B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J. Immunol. 152:4749-4757.
25. Li C, Wong WH. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A. 98:31-36. http://dx.doi.org/10.1073/pnas.98.1.31.
26. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstrin R, Springer T, Tedder TF, Todd RF. 1995. Leukocyte typing V, vol 1. Oxford University Press, Oxford, United Kingdom.
27. Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. 1991. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 173:1083-1089. http://dx.doi.org/10.1084/jem.173.5.1083.
28. Hutt-Fletcher LM. 2007. Epstein-Barr virus entry. J. Virol. 81:7825-7832. http://dx.doi.org/10.1128/JVI.00445-07.
29. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:2309-2318.
30. Hutt-Fletcher LM, Chesnokova LS. 2010. Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection. Virulence 1:395-398. http: //dx.doi.org/10.4161/viru.1.5.12546.
31. Kwong YL, Lee CP, Chan TK, Chan LC. 1994. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am. J. Clin. Pathol. 102:30-35.
32. Kieff E, Rickinson AB. 2007. Epstein-Barr virus and its replication, p 2603-2655. In Knipe DM, Howley PM (ed), Fields virology, vol 2. Lippincott, Williams & Wilkins, Philadelphia, PA.
33. Price AM, Tourigny JP, Forte E, Salinas RE, Dave SS, Luftig MA. 2012. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kappaB activation. J. Virol. 86:11096 -11106. http://dx.doi.org/10.1128/JVI.01069-12.
34. Doyle JM, Gao J, Wang J, Yang M, Potts PR. 2010. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 39:963-974. http://dx.doi.org/10.1016/j.molcel.2010.08.029.
35. Luxembourg AT, Cooper NR. 1994. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J. Immunol. 153:4448-4457.
36. Sugano N, Chen W, Roberts ML, Cooper NR. 1997. Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J. Exp. Med. 186:731-737. http://dx.doi.org/10.1084/jem.186.5.731.
37. Tanner JE, Alfieri C, Chatila TA, Diaz-Mitoma F. 1996. Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220. J. Virol. 70:570-575.
38. D'Addario M, Libermann TA, Xu J, Ahmad A, Menezes J. 2001. Epstein-Barr virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways. J. Mol. Biol. 308:501-514. http://dx.doi.org/10 .1006/jmbi.2001.4589.
39. Sista ND, Pagano JS, Liao W, Kenney S. 1993. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl. Acad. Sci. U. S. A. 90:3894-3898. http: //dx.doi.org/10.1073/pnas.90.9.3894.
40. Bouillie S, Barel M, Frade R. 1999. Signaling through the EBV/C3d receptor (CR2, CD21) in human B lymphocytes: activation of phosphatidylinositol 3-kinase via a CD19-independent pathway. J. Immunol. 162:136-143.
41. Valencia SM, Hutt-Fletcher LM. 2012. Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells. J. Virol. 86:2-10. http://dx.doi.org/10.1128/JVI.05883-11.
42. Carel JC, Myones BL, Frazier B, Holers VM. 1990. Structural require-ments for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J. Biol. Chem. 265:12293-12299.
43. Alfieri C, Birkenbach M, Kieff E. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181:595-608. http://dx.doi .org/10.1016/0042-6822(91)90893-G.
44. Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G, Farrell PJ. 1999. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J. Virol. 73:4678-4688.
45. Feng Y, Gao J, Yang M. 2011. When MAGE meets RING: insights into biological functions of MAGE proteins. Protein Cell 2:7-12. http://dx.doi .org/10.1007/s13238-011-1002-9.
46. Sang M, Wang L, Ding C, Zhou X, Wang B, Lian Y, Shan B. 2011. Melanoma-associated antigen genes-an update. Cancer Lett. 302:85-90. http://dx.doi.org/10.1016/j.canlet.2010.10.021.
47. Ladelfa MF, Peche LY, Toledo MF, Laiseca JE, Schneider C, Monte M. 2012. Tumor-specific MAGE proteins as regulators of p53 function. Cancer Lett. 325:11-17. http://dx.doi.org/10.1016/j.canlet.2012.05.031.
48. Peche LY, Scolz M, Ladelfa MF, Monte M, Schneider C. 2012. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ. 19:926-936. http://dx.doi.org/10.1038 /cdd.2011.173.
49. Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, Tsokos GC, Fingeroth JD. 2013. Human complement receptor type 1/CD35 is an Epstein-Barr virus receptor. Cell Rep. 3:371-385. http://dx .doi.org/10.1016/j.celrep.2013.01.023.
50. Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT. 1993. Functional dissection of the CD21/CD19/TAPA-1/ Leu-13 complex of B lymphocytes. J. Exp. Med. 178:1407-1417. http://dx .doi.org/10.1084/jem.178.4.1407.
51. Tedder TF, Inaoki M, Sato S. 1997. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6:107-118. http://dx.doi.org/10.1016/S1074-7613(00)80418-5.
52. D'Addario M, Ahmad A, Morgan A, Menezes J. 2000. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NFkappaB involving PKC, PI3-K and tyrosine kinases. J. Mol. Biol. 298:765-778. http://dx.doi.org/10.1006/jmbi.2000.3717.
53. Hurley EA, Thorley-Lawson DA. 1988. B cell activation and the establishment of Epstein-Barr virus latency. J. Exp. Med. 168:2059-2075. http: //dx.doi.org/10.1084/jem.168.6.2059.
54. Marzluff WF, Gongidi P, Woods KR, Jin J, Maltais LJ. 2002. The human and mouse replication-dependent histone genes. Genomics 80:487-498. http://dx.doi.org/10.1006/geno.2002.6850.
55. Izzo A, Kamieniarz K, Schneider R. 2008. The histone H1 family: specific members, specific functions? Biol. Chem. 389:333-343. http://dx.doi.org /10.1515/BC.2008.037.
56. Yang SM, Kim BJ, Norwood Toro L, Skoultchi AI. 2013. H1 linker histone promotes epigenetic silencing by regulating both DNA methylation and histone H3 methylation. Proc. Natl. Acad. Sci. U. S. A. 110: 1708-1713. http://dx.doi.org/10.1073/pnas.1213266110.